JP2022546454A5 - - Google Patents

Info

Publication number
JP2022546454A5
JP2022546454A5 JP2022513347A JP2022513347A JP2022546454A5 JP 2022546454 A5 JP2022546454 A5 JP 2022546454A5 JP 2022513347 A JP2022513347 A JP 2022513347A JP 2022513347 A JP2022513347 A JP 2022513347A JP 2022546454 A5 JP2022546454 A5 JP 2022546454A5
Authority
JP
Japan
Prior art keywords
composition
item
use according
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048500 external-priority patent/WO2021041878A1/en
Publication of JP2022546454A publication Critical patent/JP2022546454A/ja
Publication of JP2022546454A5 publication Critical patent/JP2022546454A5/ja
Priority to JP2025010364A priority Critical patent/JP2025061790A/ja
Pending legal-status Critical Current

Links

JP2022513347A 2019-08-30 2020-08-28 がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン Pending JP2022546454A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025010364A JP2025061790A (ja) 2019-08-30 2025-01-24 がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962894047P 2019-08-30 2019-08-30
US62/894,047 2019-08-30
US201962895320P 2019-09-03 2019-09-03
US62/895,320 2019-09-03
US201962916935P 2019-10-18 2019-10-18
US62/916,935 2019-10-18
PCT/US2020/048500 WO2021041878A1 (en) 2019-08-30 2020-08-28 Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025010364A Division JP2025061790A (ja) 2019-08-30 2025-01-24 がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン

Publications (2)

Publication Number Publication Date
JP2022546454A JP2022546454A (ja) 2022-11-04
JP2022546454A5 true JP2022546454A5 (cg-RX-API-DMAC7.html) 2023-09-05

Family

ID=74683405

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513347A Pending JP2022546454A (ja) 2019-08-30 2020-08-28 がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
JP2025010364A Pending JP2025061790A (ja) 2019-08-30 2025-01-24 がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025010364A Pending JP2025061790A (ja) 2019-08-30 2025-01-24 がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン

Country Status (14)

Country Link
US (1) US20220195065A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021943A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022546454A (cg-RX-API-DMAC7.html)
KR (1) KR20220054649A (cg-RX-API-DMAC7.html)
CN (2) CN118924895A (cg-RX-API-DMAC7.html)
AU (1) AU2020337999A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003707A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152776A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000495A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022003580A2 (cg-RX-API-DMAC7.html)
IL (1) IL290871A (cg-RX-API-DMAC7.html)
MX (1) MX2022002524A (cg-RX-API-DMAC7.html)
PE (1) PE20221404A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US20230416402A1 (en) * 2022-03-03 2023-12-28 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2
AR134292A1 (es) * 2023-11-13 2025-12-17 Dragonfly Therapeutics Inc Métodos para tratar el cáncer mediante el uso de proteínas de unión multiespecíficas que se unen a nkg2d, cd16 y her2
WO2026071855A1 (ko) * 2024-09-30 2026-04-02 주식회사 피노바이오 비대칭 항체를 포함하는 항체-이중 약물 접합체 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP4273258A3 (en) * 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN111788225B (zh) * 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
MX2020008333A (es) * 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) * 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d

Similar Documents

Publication Publication Date Title
JP7257364B2 (ja) 抗cd137抗体
JP7436477B2 (ja) TGF-β受容体融合タンパク質医薬組成物およびその使用
JP7352973B2 (ja) 二重特異性抗体及びその使用
JP6967515B2 (ja) Pd−1抗体
JP2020015719A (ja) ペルツズマブ変異体及びその評価
CN102884084B (zh) 抗her2抗体及组合物
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
JP7728185B2 (ja) 共有結合型多重特異性抗体
JP2011501656A5 (cg-RX-API-DMAC7.html)
CN114761433B (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2022532991A5 (cg-RX-API-DMAC7.html)
CN113135995B (zh) 抗her3单克隆抗体及其应用
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CA3180188A1 (en) Anti-flt3 antibodies and compositions
TW201925230A (zh) 以抗egfr療法治療癌症的組成物及方法
KR20220153615A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN104861068A (zh) 一种全人源抗her3抗体及含有该抗体的组合物和其用于制备治疗her3相关疾病的药物中的用途
CN103417965B (zh) 一种含有抗vegf抗体的药物组合物
JP2026506070A (ja) 抗cntn4抗体及びその使用
WO2023093744A1 (zh) 一种双特异性抗原结合蛋白
CA3229542A1 (en) Anti-her2 antibodies and methods of use thereof
CN117545508A (zh) 用于癌的治疗和/或预防的药品